NCT07734038
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 55 words
- Start date changed from estimate of Oct 1, 2026 to Sep 16, 2026
- Secondary endpoints: details revised at 2 of 13 entries
- Notable Recruitment opened
- Start date: Oct 7, 2026 to Oct 1, 2026
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (13)
Show 8 moreShow less
Arms and interventions
Patients receive SOC zanubrutinib PO QD or BID per physician discretion on days 1-28 of each cycle. Starting with cycle 4, patients also receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 15 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, bone marrow biopsy and aspiration, and CT or MRI throughout the study.
Patients receive SOC zanubrutinib PO QD or BID per physician discretion on days 1-28 of each cycle. Starting with cycle 4, patients also receive venetoclax PO QD on days 1-28 of each cycle. Cycles repeat every 28 days for up to 27 cycles in the absence of disease progression or unacceptable toxicity. Additionally, patients undergo blood sample collection, bone marrow biopsy and aspiration, and CT or MRI throughout the study.
Procedures: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging
Drugs: Venetoclax, Zanubrutinib
Sites
1 site in 1 country
- Ohio State University Comprehensive Cancer CenterColumbus, Ohio, United States